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The interferon-producing plasmacytoid dendritic cells
(pDCs) share common progenitors with antigen-pre-
senting classical dendritic cells (cDCs), yet they
possess distinct morphology and molecular features
resembling those of lymphocytes. It is unclear
whether the unique cell fate of pDCs is actively
maintained in the steady state. We report that the
deletion of transcription factor E2-2 from mature
peripheral pDCs caused their spontaneous differenti-
ation into cells with cDC properties. This included the
loss of pDCmarkers, increase in MHC class II expres-
sion and T cell priming capacity, acquisition of
dendritic morphology, and induction of cDC signature
genes. Genome-wide chromatin immunoprecipitation
revealed direct binding of E2-2 to key pDC-specific
and lymphoid genes, as well as to certain genes
enriched in cDCs. Thus, E2-2 actively maintains the
cell fate of mature pDCs and opposes the ‘‘default’’
cDC fate, in part through direct regulation of lineage-
specific gene expression programs.
INTRODUCTION
Dendritic cells (DCs) of the immune system efficiently recognize
pathogens through pattern recognition receptors such as Toll-
like receptors (TLRs), secrete multiple cytokines, and activate
naive T cells during primary responses. The latter property
distinguishes them among other innate immune cell types and
establishes a key link between innate and adaptive immunity
(Steinman and Idoyaga, 2010). In humans and in experimental
animals, DCs are represented by two major lineages, classical
or conventional DCs (cDCs) and plasmacytoid DCs (pDCs)
(Merad and Manz, 2009). The cDCs show high surface expres-
sion of MHC class II (MHC II) and of the integrin CD11c, and
even in the steady state have outstanding capacity for naive
T cell priming. Murine cDCs comprise two phenotypically and
functionally distinct subsets, distinguishedbysurface expression
of CD8a in the lymphoid organs and CD103 in tissues; similar
subsets have been proposed for the human cDCs (Shortman
andHeath, 2010). In contrast, pDCs are specialized in TLR-medi-Iated recognition of viral nucleic acids and high-level secretion of
type I interferon (IFN) in response to viruses (Liu, 2005; Swiecki
and Colonna, 2010). The unique IFN secretion capacity of pDCs
is facilitated by baseline expression of IRF7, the transcriptional
‘‘master regulator’’ of IFN response; conversely, it is tightly
controlled by pDC-specific inhibitory receptors such as human
ILT7 and BDCA-2 and murine Siglec-H (Gilliet et al., 2008). The
pDCs express low MHC II and CD11c and display distinct
markers such as CD45RA (also known as B220), Ly-6c, and
Bst2, which is highly specific for murine pDCs in the steady state
(Blasius et al., 2006) and also serves as ILT7 ligand in humans
(Cao et al., 2009). The pDCs in the steady state have poor T cell
stimulatory capacity, whereas upon activation by viruses and
TLR ligands, they can efficiently present and cross-present Ag
to T cells (Villadangos and Young, 2008).
Multiple lines of evidence suggest that cDCs and pDCs are
closely related. First, both lineages are postulated to develop
in the same pathway (Liu and Nussenzweig, 2010) from a bone
marrow (BM) progenitor termed common DC progenitor (CDP)
or pro-DC (Naik et al., 2007; Onai et al., 2007). This common
developmental pathway critically depends on cytokine Flt3
ligand (Flt3L), its receptor Flt3, and downstream transcription
factor Stat3 (Schmid et al., 2010). Second, genome-wide
expression profiles of human and murine pDCs are most similar
to those of the respective cDCs but distinct from lymphocytes or
myeloid cells (Robbins et al., 2008). Third, in vitro activation by
viruses or cytokines induces human pDC differentiation into cells
with morphological and functional properties of cDCs (Soumelis
and Liu, 2006). In contrast, pDCs differ from cDCs in several key
aspects. Most obviously, cDCs exhibit typical DC morphology
with prominent cytoplasmic veils and protrusions (dendrites),
whereas pDCs have round morphology of a secretory lympho-
cyte. Indeed, pDCs displaymany salient features of lymphocytes
such as relatively long lifespan on the order of weeks, contrasted
with cDC turnover within several days (Liu et al., 2007; O’Keeffe
et al., 2002). In particular, pDCs show important molecular simi-
larities with B lymphocytes, including shared markers (B220),
nucleic acid-sensing TLRs (TLR7, TLR9), transcription factors
(SpiB, Bcl11a), and a B cell receptor (BCR)-like signaling
pathway that inhibits IFN secretion (Crozat et al., 2010; Gilliet
et al., 2008). Moreover, pDCs express B cell-specific pIII isoform
of MHC II transactivator CIITA, in contrast to the pI isoform ex-
pressed exclusively by cDCs (LeibundGut-Landmann et al.,
2004). Finally, pDCs express multiple transcripts specific for
developing T and B lymphocytes, such as human PTCRA andmmunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc. 905
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Figure 1. E2-2 Deletion in the Periphery
Causes Spontaneous pDC Differentiation
(A) Recombination efficiency in the pDCs from
Itgax-Cre deleter strain, as measured by Cre-
inducible EYFP reporter expression in Itgax-Cre+
Gt(ROSA)26Sor-EYFP+ mice. Shown are repre-
sentative histograms of EYFP fluorescence in
gated CD11clo Bst2+ pDCs from the BM or spleen
and in splenic CD11chi MHC II+ cDCs as a control.
The positive threshold of EYFP fluorescence is
indicated by a dashed line.
(B) The pDC population within Cre reporter-posi-
tive cells in the Gt(ROSA)26Sor-EYFP+ Itgax-Cre+
Tcf4flox/- conditional knockout (CKO) or Gt(ROSA)
26Sor-EYFP+ Itgax-Cre+ control (Ctrl) mice.
Shown are staining profiles of EYFP+ cells in the
BM or spleen, with the fraction of CD11clo Bst2+
pDCs indicated.
(C) DC populations within Cre reporter-positive
splenocytes in control and CKO mice. Shown are
staining profiles of EYFP+ cells; highlighted are
CD11chi B220 cDCs (blue), CD11clo B220+
pDCs (green), and the CD11chi B220lo cDC-like
population (red).
(D) The fraction among total splenocytes of the cell
populations shown above (mean ± SD of three
animals per genotype). n.s., not significant.
(E) Cell surface phenotype of the B220lo cDC-like
population. Shown are staining histograms of
EYFP+ splenocyte populations shown in (C),
including pDCs from control mice and cDCs and
the B220lo cDC-like cells from CKO mice. Repre-
sentative of three CKO animals.
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E2-2 Maintains the Cell Fate of pDCsmurine Dntt and Ccr9 (Reizis, 2010). Thus, the lineage identity of
pDCs remains controversial, and their relationship to cDCs
requires further genetic evidence.
Recently, we have shown that class I basic helix-loop-helix
transcription factor (E protein) E2-2 (official symbol Tcf4) is a crit-
ical regulator of pDC lineage specification in mice and in humans
(Cisse et al., 2008). E proteins are important regulators of lym-
phopoiesis, with other family members E2a and HEB controlling
the development of B and T lymphocytes, respectively (D’Cruz
et al., 2010; Kee, 2009). The activity of E proteins is antagonized
by Id family transcription factors such as Id2, which prevent
E protein binding to DNA. Murine and human mature pDCs
express high E2-2 but low levels of Id2, whose overexpression
blocks pDC development (Cisse et al., 2008; Nagasawa et al.,
2008; Spits et al., 2000). E2-2-deficient hematopoietic cells
cannot give rise to pDCs, whereas pDCs from mice and from
human patients heterozygous for E2-2 manifest aberrant surface
phenotype and defective IFN secretion (Cisse et al., 2008). In
particular, murine Tcf4+/ pDCs show reduced expression of
the genes that are specific for pDCs (Irf7) or shared between
pDCs and lymphocytes (Dntt, Ccr9, Spib).
Based on these results, we hypothesized that E2-2 expression
diverts pDCs from the common DC developmental pathway and
imparts them with ‘‘lymphoid’’ features (Reizis, 2010). In this906 Immunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc.scenario, the resulting pDC fate can be either irreversibly
‘‘locked’’ by epigenetic mechanisms or actively enforced
by the presence of E2-2. To test these possibilities, we analyzed
the consequences of constitutive or inducible loss of E2-2 in the
peripheral pDCs in vivo. We now report that E2-2-deficient
mature pDCs spontaneously acquire phenotypic, morpholog-
ical, and functional properties of cDCs. Furthermore, we provide
evidence that E2-2 directly activates pDC-specific gene expres-
sion program andmight repress genes associated with the alter-
native cDC lineage. Therefore, continuous E2-2 expression in
mature pDCs is required to maintain their unique lineage identity
and antagonize the ‘‘default’’ cDC cell fate.
RESULTS
Constitutive Deletion of E2-2 in Peripheral pDCs
Generates a cDC-like Population
To test the role of E2-2 in pDC maintenance, we performed
stage-specific recombination of the conditional Tcf4 allele
(Tcf4flox) in mature peripheral pDCs. To this end, we used the
Itgax-Cre (also known as CD11c-Cre) deleter strain, in which
recombination occurs in 50%–60% of BM pDCs but increases
to 90% in splenic pDCs (Figure 1A; Caton et al., 2007). To
increase the frequency and visibility of pDCs that underwent
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E2-2 Maintains the Cell Fate of pDCsCre recombination, we have combined a conditional and
a germline null Tcf4 alleles and introduced Cre-inducible
enhanced yellow fluorescent protein reporter allele (Gt(ROSA)
26Sor-EYFP). In the resulting Itgax-Cre+ Tcf4flox/ Gt(ROSA)
26Sor-EYFP+ conditional deletion mice, EYFP+ pDCs were
readily detectable in the BM but completely absent from the
spleen (Figure 1B), suggesting that some pDCs develop but do
not persist in the periphery. Notably, the analysis of splenic
EYFP+ cells revealed a newCD11chiB220lo population appearing
as an intermediate between pDCs and cDCs (Figures 1C
and 1D). These cells lacked pDC markers Bst2 and Ly-6c but
expressed high levels of MHC II and CD8, consistent with the
cDC phenotype (Figure 1E).
We also analyzed fully conditional Itgax-Cre+ Tcf4flox/flox mice,
which demonstrate a partial deletion of splenic pDCs (Cisse
et al., 2008). Although less conspicuous without a Cre reporter,
the same CD11chiB220lo MHC II+ Bst2 population was mark-
edly elevated in the Itgax-Cre+ Tcf4flox/flox spleens (Figure S1
available online). On the other hand, this population was not
observed in the animals reconstituted with Tcf4/ hematopoi-
etic progenitors, in which pDC development in the BM is
completely blocked (data not shown). Therefore, this population
probably represents the progeny of pDCs that escape early E2-2
deletion in the BM and lose E2-2 only in the periphery. These
data suggest that the loss of E2-2 in peripheral pDCs causes
their spontaneous differentiation into cells with cDC phenotype.
Inducible Deletion of E2-2 in pDCs Causes Acquisition
of cDC Phenotype
To analyze the fate of mature pDCs after E2-2 deletion, we used
Gt(ROSA)26Sor-CreER deleter mice that express tamoxifen
(Tmx)-inducible Cre recombinase. High-dose Tmx administra-
tion to Gt(ROSA)26Sor-CreER+ Tcf4flox/flox mice leads to rapid
pDC loss (Cisse et al., 2008). After the induction with a lower
dose of Tmx, splenic pDCs were present in normal numbers at
days 2–4 but largely disappeared by day 9 (data not shown).
Because pDCs are relatively long lived, we hypothesized that
such rapid depletion may be caused by a defect in peripheral
pDCs. We therefore analyzed E2-2-deficient splenic pDCs on
day 6 after Tmx treatment, when pDC numbers were reduced
by 50% (Figure 2A). Notably, pDC survival at this stage was
not impaired (Figure S2), suggesting that pDCs may undergo
phenotypic conversion rather than cell death.
To test whether acute E2-2 loss depletes pre-existing mature
pDCs, Gt(ROSA)26Sor-CreER+ Tcf4flox/flox mice were fed with
nucleoside analog bromodeoxyuridine (BrdU) for 2 weeks
(‘‘pulse’’), followed by BrdU withdrawal (‘‘chase’’) at the start of
Tmx treatment. In contrast to the CD8+ cDCs that largely turned
over after 8 days of chase (corresponding to day 6 after Tmx
treatment), a substantial fraction of pDCs retained BrdU
(Figure 2B). Notably, both BrdU+ (i.e., pre-existing) and BrdU
(i.e., newly generated) splenic pDCs were reduced in Gt(ROSA)
26Sor-CreER+ Tcf4flox/flox mice at that point (Figure 2C). Further-
more, the analysis of CD8+ cDCs in CKO spleens revealed
a novel B220+ population that was 50% BrdU+ (Figure 2D).
Because cDCs do not express E2-2 (Cisse et al., 2008) and their
proliferation was not changed by E2-2 deletion (Figure S2),
the B220+ BrdU+ cDCs may have developed from pre-existing
B220+ cells such as pDCs. Thus, the induction of E2-2 lossIfrom mature splenic pDCs leads to their depletion, probably
through differentiation into B220+ cells with CD8+ cDC
phenotype.
To trace the fate of splenic pDCs after induced E2-2 deletion,
we used human pre-T cell receptor a (PTCRA) transgenic mice
that express enhanced green fluorescent protein (EGFP) specif-
ically in pDCs (Shigematsu et al., 2004). Because EGFP protein is
very stable without cell division andmarks immediate progeny of
EGFP+ cells (Boursalian et al., 2004), PTCRA-EGFP expression
facilitates the tracing of pDC progeny. In control PTCRA-
EGFP+ animals 6 days after Tmx treatment, splenic B220+
EGFP+ pDCs were uniformly Bst2+ CD11clo MHC IIlo (Figure 2E).
In contrast, >30% of B220+ EGFP+ splenocytes in Tmx-treated
PTCRA-EGFP+ Gt(ROSA)26Sor-CreER+ Tcf4flox/flox animals
lost Bst2 expression; this Bst2 pDC fraction showed a particu-
larly strong upregulation of CD11c and MHC II nearly to the level
of cDCs. Furthermore, B220+ EGFP+ E2-2-deficient cells down-
regulated CCR9 and Ly-6c and upregulated CD8 in a larger frac-
tion of cells (Figure 2F and data not shown). The increase in MHC
II occurred in both CD8lo and CD8hi pDC populations (data not
shown), suggesting that it is independent of the heterogeneous
CD8 expression on pDCs.
To testwhether similar phenotypic conversionmaybeobserved
in vitro, E2-2 deletion was induced in Flt3L-supplemented BM
cultures. The expansion of CD11chi cDC-like cells at the expense
of pDCs was observed as early as 2 days after Tmx addition
to PTCRA-EGFP+ Gt(ROSA)26Sor-CreER+ Tcf4flox/flox cultures
(Figure S2). The rapid phenotypic changes suggest that E2-2
protein levels closely follow the transcript levels after deletion.
Altogether, these data demonstrate that acute loss of E2-2 from
mature pDCs causes their spontaneous conversion into cDC-like
cells.
In view of these results, we tested whether pDC abnormalities
in Tcf4+/mice (Cisse et al., 2008) could be intrinsic to peripheral
pDCs. Indeed, Tcf4+/ pDCs showed increased expression of
CD8, CD11c, and MHC II only in the spleen, not in the BM
(data not shown). Furthermore, in PTCRA-EGFP+ Tcf4+/ mice,
EGFP+ pDCs upregulated CD11c and MHC II expression (Fig-
ure S2), as observed after E2-2 deletion (Figure 2E). Thus,
peripheral pDCs in Tcf4+/ mice spontaneously upregulate
cDC markers, suggesting that reduced E2-2 expression causes
phenotypic conversion to cDC-like cells.
E2-2-Deficient pDCs Acquire cDC Properties
To analyze the morphology of pDCs after acute E2-2 loss, sorted
EGFP+ pDCs from Tmx-treated PTCRA-EGFP+ control and
Gt(ROSA)26Sor-CreER+ Tcf4flox/flox mice were stained for actin
cytoskeleton. As shown in Figure 3A, the majority (72%) of
control pDCs had a characteristic round perinuclear actin stain-
ing; the remaining cells showed only minimal changes of cell
shape or actin cytoskeleton, and none had dendrites. In contrast,
67% of E2-2-deficient pDCs showed irregular shape and/or
prominent actin remodeling, and 17% had overt dendrites
similar to those of cDCs (Figures 3A and 3B).
Next, we tested the Ag presentation capacity of E2-2-deficient
pDCs. Consistent with their lowMHC II expression, unstimulated
splenic pDCs cannot prime CD4+ T cell responses (Young et al.,
2008). Indeed, sorted CD11clo EGFP+ pDCs from control
PTCRA-EGFP+ animals failed to induce proliferation of naivemmunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc. 907
Ccr9 CD8 CD11b
Ctrl CKO
11
6
1.1
0.3B
st
2
CD11c
BrdU- BrdU+
Ctrl
CKO
6 8
1 1
BrdU
B2
20
Ctrl
CKO
A B
C
E
F
0.3
0.3
4
Ctrl
6 32
0.3
31
CD11cBst2B220
CKO
M
H
C
 II
EG
FP
D
CD8+ T
CD8+ cDC
PDC
BrdU
18
11
33
cDC PDC
0
5
10
15
20
Ctrl CKO
0
10
20
30
40
50
C
el
ls
, 1
04 P=0.0008n.s.
Ctrl CKO
Figure 2. Inducible Loss of E2-2 in Mature pDCs
Causes Differentiation into cDC-like Cells
(A) Reduction of PDC numbers shortly after E2-2 deletion.
Tamoxifen (Tmx)-inducible Gt(ROSA)26Sor-CreER+
Tcf4flox/flox CKO mice or Cre-negative littermate controls
(Ctrl) were treated with Tmx and analyzed on day 6 after
the last administration. Shown are absolute numbers of
splenic cDC (CD11chi MHC II+) and PDC (CD11clo Bst2+)
in the individual CKO and control mice. n.s., not significant.
(B) BrdU labeling of pre-existing pDCs. Tmx-inducible
CKO and control mice were kept on BrdU for 14 days,
followed by simultaneous 3 day Tmx treatment and BrdU
withdrawal for 8 days. Shown is BrdU incorporation in
the splenic CD8+ T cells, CD8+ CD11chi cDCs, or CD11clo
Bst2+ pDCs from control mice. The threshold of high-level
BrdU staining is indicated by the dashed line.
(C) The fraction of pDCs among BrdUhi or BrdU spleno-
cytes pooled from 3–4 control and CKO animals.
(D) BrdU incorporation and B220 expression in the splenic
CD8+ CD11chi MHC II+ cDCs from control and CKO mice.
The percentages of B220+ BrdU and B220+ BrdU+ cells
are indicated.
(E) Cell surface phenotype of pDCs after Tmx-induced
E2-2 deletion in PTCRA-EGFP reporter mice. Conditional
PTCRA-EGFP+ Gt(ROSA)26Sor-CreER+ Tcf4flox/flox (CKO)
mice or Cre-negative littermate controls (Ctrl) were treated
with Tmx and analyzed 6 days later. Shown are the frac-
tions among total splenocytes and the staining profiles of
B220+ EGFP+ pDCs, with the CD11chi MHC II+ cDC gate
indicated. Whereas the fraction of EGFP+ pDCs was
variable because of partial EGFP expression in pDCs
(Shigematsu et al., 2004), their phenotypic changes are
representative of >5 CKO animals.
(F) Staining histograms of gated B220+ EGFP+ pDCs from
CKO and control mice (representative of three indepen-
dent experiments).
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E2-2 Maintains the Cell Fate of pDCsallogeneic CD4+ T cells (Figure 3C). In contrast, CD11clo EGFP+
pDCs from Tmx-treated Gt(ROSA)26Sor-CreER+ Tcf4flox/flox
mice induced a significant allogeneic response. A similar
increase in T cell proliferation was observed in ovalbumin-
specific priming of TCR transgenicCD4+T cells byE2-2-deficient
pDCs from ovalbumin-pulsed animals (data not shown). Thus,
E2-2-deficient peripheral pDCs acquire dendritic morphology
and capacity for CD4+ T cell priming, the salient features of cDCs.
E2-2-Deficient pDCsUpregulate cDC-AssociatedGenes
To characterize gene expression changes underlying the
observed phenotypic and morphological conversion, we exam-908 Immunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc.ined global expression profile of peripheral
pDCs after E2-2 deletion. Control and Gt
(ROSA)26Sor-CreER+ Tcf4flox/flox animals were
treated with Tmx, and CD11clo Bst2+ pDCs
were sorted on days 4 or 6 and analyzed by
Affymetrix expression microarrays. The rigorous
definition of pDCs as Bst2+ and the additional
4 day time point were used to focus on the
earliest and most reliable changes of gene
expression. Principal component analysis
(PCA) was used to define probe sets that were
coordinately induced or decreased in CKO
pDCs at both time points (60 and 70 probes,respectively, out of 24,505 total probes; Figure 4A; Table S1).
The upregulated set included three probes for Cd8a, consistent
with CD8 upregulation in E2-2-deficient pDCs (Table 1). Further-
more, many of the upregulated (16/60) and downregulated
(14/70) probes were correspondingly changed in the previous
microarray analysis of Tcf4+/ pDCs (Table 1; Table S1).
Next, we used PCA to analyze normal expression profiles of
the differentially expressed genes. No clear pattern could be
established among the downregulated genes, although several
of these (Matn2, Fcrla, Sla2, Notch3) are prominently enriched
in pDCs. In contrast, the upregulated genes comprised two prin-
cipal components: enriched in cDCs (16/60 probes) and
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Figure 3. E2-2-Deficient pDCs Acquire Morpho-
logical and Functional Properties of cDCs
Conditional PTCRA-EGFP+ Gt(ROSA)26Sor-CreER+
Tcf4flox/flox (CKO) mice or Cre-negative littermate controls
(Ctrl) were treated with Tmx, and 6–7 days later splenic
EGFP+ CD11clo/int pDCs and EGFP CD11chi cDCs were
isolated by flow cytometry.
(A) Representative confocal photomicrographs of pDCs
stained for actin cytoskeleton (phalloidin, red) and nuclear
DNA (DAPI, blue). For control cells, the typical pDC
morphology (72% of all cells) and the most extreme
example of actin remodeling are shown. For CKO cells,
the examples of pDC morphology (33% of all cells), actin
remodeling, and dendrites are shown, along with sorted
cDCs as a positive control.
(B) Quantitative analysis of pDC morphology. Confocal
microscopy images shown in (A) were scored for irregular
cell shape, actin cytoskeleton remodeling, and dendrites,
and cumulative scores of individual control (n = 55) and
CKO (n = 75) cells are shown.
(C) T cell priming capacity of pDCs. The pDCs or cDCs
were sorted as above and cultured alone or with purified
allogeneic CD4+ T cells, and thymidine incorporation was
determined 72 hr later (mean ± SD of triplicate cultures).
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E2-2 Maintains the Cell Fate of pDCsenriched in cDCs and B cells (9/60 probes) (Figure 4B). More-
over, seven of the upregulated genes belong to the evolutionarily
conserved signature that distinguishes cDCs frompDCs (Table 1;
Table S1; Robbins et al., 2008). Despite the induction of CD8,
a substantial fraction of the upregulated genes (14/60) is charac-
teristic of the CD8 rather than CD8+ cDC subset (Figure 4C;
Table S1). Thus, the resulting CD8+ cDC-like cells appear distinct
from the bona fide CD8+ cDCs and instead may resemble the
recently described CD8-expressing cDC subset related to
CD8 cDCs and pDCs (Bar-On et al., 2010). Functionally, several
upregulated genes (Fscn1, Pak1, Dock4) control cytoskeletal
organization, including Fscn1 as a known regulator of cDC
morphology (Al-Alwan et al., 2001). Furthermore, MHC II presen-
tation pathway genes (H2-DMb2, H2-Ob) were induced,
consistent with the acquisition of cDC properties and the corre-
sponding morphological and functional switch.
Next, cDCs and pDCs independently sorted from Gt(ROSA)
26Sor-CreER+ Tcf4flox/flox mice 5 days after Tmx treatment
were analyzed by quantitative RT-PCR (qPCR). This analysis
confirmed microarray results and expression patterns in pDCs
and cDCs for the relevant differentially expressed genes (Table 1;
Figure 4D). In addition, CKO pDCs showed downregulation of
pDC-enriched transcription factors Spib and Bcl11a and induc-
tion of Id2 andCIITA isoform pI, both of which are highly enriched
in cDCs compared to pDCs (Figure 4D). The downregulation of
Bcl11a after E2-2 deletion was confirmed in BM-derived pDC
cultures (Figure S3). Overall, the changes of transcription factor
profile are consistent with the onset of conversion to cDC-like
cells by E2-2-deficient pDCs.Immunity 33, 905–E2-2 Directly Controls the Expression
Program of pDCs
The data so far indicate that E2-2maintains pDC
cell fate and prevents spontaneous conversion
into cDC-like cells. To test whether E2-2 medi-
ates these effects through direct binding to therelevant genes, we performed chromatin immunoprecipitation
followed by genome-wide promoter microarray hybridization
(ChIP-on-chip) in the human pDC cell line CAL-1. The resulting
probabilities of probe binding (pXbar) by E2-2-associated chro-
matin yielded binding profiles of E2-2 across the 50 regions of
genes (Figures 5A and 5B). By using stringent criteria (pXbar <
0.01, pXbar ratio of E2-2 and control ChIP < 0.1), we have defined
high-confidence list of 2,477 genes (corresponding to 4,369
probes, out of 17,000 genes and 474,392 probes total) as
E2-2 binding targets (Table S2). The list included several genes
reduced in murine E2-2-deficient and/or Tcf4+/ pDCs (SPIB,
IRF7, FCRLA, SLA2, DNTT), suggesting these genes as
conserved E2-2 targets (Table 2). Notably, the target list included
20 of 55 (36%) human pDC-specific genes compared to 6 of 47
(13%) genes expressed in both pDCs and myeloid cells; further-
more, 23% of conserved pDC ‘‘signature’’ genes (Robbins et al.,
2008) represented E2-2 binding targets (Table S3). Indeed,
several uniquely pDC-specific genes such as LILRA4 (encoding
ILT7; Cao et al., 2006), PACSIN1 (Robbins et al., 2008), and
CD2AP (Marafioti et al., 2008) were strongly bound by E2-2
(Table 2; Figure 5A). Moreover, E2-2 binding targets (Table 2)
included key functional genes in pDCs such as transcription
factors (SPIB, IRF7, CIITA pIII), components of TLR signaling
pathway (TLR9, TLR7-TLR8, UNC93B1, BTK), and BCR-like
signaling cascade that inhibits IFN response (TYROBP,PIK3AP1,
BLNK) (Gilliet et al., 2008). These data suggest that E2-2 directly
controls the specific gene expression program of mature pDCs.
In addition to pDC-specific genes, E2-2 target list included
genes associated with the alternative cDC fate, such as ITGAX916, December 22, 2010 ª2010 Elsevier Inc. 909
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Figure 4. E2-2-Deficient pDCs Upregulate cDC-Enriched Genes
(A) Genes coordinately changed in pDCs on days 4 and 6 after E2-2 deletion. The pDCs were sorted from Gt(ROSA)26Sor-CreER+ Tcf4flox/flox (CKO) mice or
littermate controls 4 and 6 days after Tmx treatment and subjected to genome-wide expression profiling via microarrays. Principal component analysis (PCA)
was used to identify probes up- or downregulated in CKO samples on both days. Top panels show expression graphs of individual probes (gray) and the principal
component (red); lower panels show expression graphs for the indicated representative probes. Data represent log hybridization intensity of probes (average ±
SD of duplicate array samples).
(B) Expression profile of the genes upregulated in E2-2-deficient pDCs. For the 60 probes upregulated in pDCs after E2-2 deletion, normal expression values in
major immune cell types were derived fromGEO data set GSE9810 and subjected to PCA. Shown are expression graphs for the twomajor principal components
(cDC-enriched and cDC+B cell-enriched probes).
(C) The cDC subset specificity of the upregulated genes. The 60 probes upregulated in pDCs after E2-2 deletion were queried for their expression in the normal
CD8 and CD8+ cDC subsets (GEO data set GSE9810). Shown is log-ratio plot comparison of expression values in CD8 and CD8+ cDCs, with the probes
overexpressed >3-fold highlighted in red and green, respectively. The three probes for Cd8a are circled.
(D) Quantitative analysis of gene expression in E2-2-deficient pDCs. The pDCs (CD11clo Bst2+) and cDCs (CD11chi Bst2) were sorted from control and CKO
animals 5 days after Tmx treatment and analyzed by qRT-PCR for microarray target genes (top row) and downregulated (middle row) and upregulated (bottom
row) transcription factors. Data represent normalized expression values relative to the control pDC sample (mean ± SD of triplicate reactions).
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Table 1. Differentially Expressed Genes in E2-2-Deficient pDCs
Gene Probe Fold Change
Fold Change
(qPCR) Tcf4+/ PDC
Expression
Pattern (PCA)
Expression
Signature
E2-2 ChIP
Target
Reduced
Notch3 1421965_s_at 2.3 n.d. down
Fcrla 1419907_s_at 2.1 3.8 down pDC yes
Matn2 1455978_a_at 2.3 2.2 down
Sla2 1437504_at 2.3 2.6 pDC yes
Increased
Cd8a 1444078_at, 1425335_at,
1440811_x_at
2.5 n.d. up
H2-DMb2 1443686_at, 1443687_x_at 2.6 2.9 up cDC+B yes
H2-Ob 1440837_at 2.4 4.1 up cDC+B cDC
Fscn1 1416514_a_at 4.1 2.9 cDC cDC
S100a4 1424542_at 4.8 4.3 up CD8 cDC
Pak1 1450070_s_at 2.7 1.8 cDC cDC
Hspa1b 1427126_at 2.1 n.d. up cDC
Tmem176a 1441811_x_at 4.0 1.7 cDC yes
1100001H23Rik 1448786_at 2.4 1.9 up cDC cDC
Sorted pDCs were analyzed by expression microarrays 4 or 6 days after Tmx-induced E2-2 deletion, and genes coordinately increased or reduced in
E2-2-deficient compared to control pDCs were defined (Table S1). Shown are select target genes with the corresponding microarray probes; average
fold change bymicroarray analysis; fold change determined by qRT-PCR in independently sorted pDCs on day 5 after Tmx treatment; >2-fold change,
if any, in pDCs from Tcf4+/mice heterozygous for E2-2 (Cisse et al., 2008); expression pattern as determined by PCA of normal expression values in
GSE9810; conserved ‘‘expression signature’’ (Robbins et al., 2008); and high-confidence E2-2 binding in human pDCs as determined by ChIP-on-ChIP
(Table S2). n.d., not done.
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(Robbins et al., 2008). Furthermore, cDC-enriched genes
induced in E2-2-deficient pDCs such as HLA-DMB, S100A4,
TMEM176A, and ID2were specifically bound by E2-2 (Figure 5B;
Table S1). Thus, E2-2 may antagonize cDC cell fate in part by
directly binding to and repressing cDC-associated genes.
DISCUSSION
Here we demonstrate that the reduction or loss of transcription
factor E2-2 from mature pDCs caused their differentiation into
cDC-like cells. In Tcf4+/ animals, peripheral pDCs showed
increased expression of cDC markers and MHC II, indicating
a ‘‘drift’’ toward cDC-like phenotype. This explains the reduced
pDC-specific gene expression and IFN secretion capacity in
murine and human Tcf4+/ pDCs (Cisse et al., 2008) and
suggests that the haploinsufficiency of E2-2 is primarily due to
the defective maintenance of peripheral pDCs. The deletion of
E2-2 from mature pDCs via constitutive stage-specific or induc-
ible deletion systems resulted in the appearance of a CD8+
cDC-like population that retained some pDC markers such as
B220 and PTCRA-EGFP. Further analysis of pDCs shortly after
E2-2 deletion confirmed the acquisition of morphological and
functional properties of cDCs and the induction of cDC gene
expression program. Because cDCs are very short lived
compared to pDCs, such differentiation accounts for the rapid
disappearance of pDCs after E2-2 deletion. Overall, these data
suggest that continuous expression of E2-2 is required to main-
tain the cell fate of mature pDCs and to prevent spontaneous cell
fate conversion and eventual loss.IA major implication of the observed pDC conversion into
cDC-like cells is that pDCs are genetically closer to cDCs than
to any other lineage. The question of pDC origin and lineage
identity has been highly controversial ever since the identifica-
tion of pDCs as a separate cell type. Whereas common BM
progenitors and dependence on Flt3 signaling suggest a close
relationship with cDCs, pDCs show evidence of lymphoid origin
such as D/J rearrangement of IgH and TCRb loci and history
of Rag1 expression (Corcoran et al., 2003; Pelayo et al., 2005;
Welner et al., 2009). Indeed, in almost every aspect of
morphology and physiology, pDCs resemble lymphocytes
(particularly B cells) more than cDCs. To explain this apparent
paradox, we proposed that pDCs are genetically and develop-
mentally related to cDCs more than to any other lineage;
however, the induction of E2-2 and the ensuing E protein-
dependent gene expression program impart the unique
lymphoid features upon pDCs (Reizis, 2010). Thus, the cDC
cell fate may represent the ‘‘default’’ differentiation pathway of
common DC progenitors, which is antagonized by E2-2 to
specify pDC lineage. Our current results strongly support this
model and extend it to demonstrate active repression of the
‘‘default’’ cDC cell fate by E2-2.
Although E2-2-deficient pDCs upregulate CD8a, they do not
seem to differentiate into the bona fide CD8+ cDCs. Indeed,
CD8+ cDC-specific genes such as Tlr3, Xcr1, or Itgae were not
increased (data not shown), whereas many CD8 cDC-enriched
genes became upregulated. Notably, a similar CD8+ cDC popu-
lation whose expression profile is related to CD8 cDCs and
pDCs was recently identified in the lymphoid organs of naive
mice via the Cx3cr1-EGFP reporter allele (Bar-On et al., 2010).mmunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc. 911
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Figure 5. Direct Binding of E2-2 to Target Genes in pDCs
(A) The binding of E2-2 to the 50 regions of pDC-specific target genes in the human pDC cell line CAL-1. Chromatin immunoprecipitated with anti-E2-2 or control
antibodies was labeled and hybridized to a microarray containing 10 kb promoter regions of 17,000 human genes. Shown are graphs of E2-2 binding prob-
ability (pXbar) over the 50 gene regions, highlighting exons (filled boxes) and transcription start sites (arrows). Horizontal axis divisions correspond to 1 kb. Regions
showing high background binding in control antibody hybridization (pXbar < 0.1) are shaded in gray. Red dots represent the regions of binding determined by
qPCR of unamplified chromatin (Cisse et al., 2008).
(B) The binding of E2-2 to the 50 regions of cDC-enriched target genes in CAL-1, shown as above.
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such as S100a4 and Trem176a are prominently expressed in
the Cx3cr1-EGFP+ but not in the classical CD8+ cDCs. More-
over, Cx3cr1-EGFP+ CD8+ cDCs express low E2-2 but require
E2-2 expression in the BM for their development, suggesting
that they arise from committed pDC progenitors that downregu-
late E2-2. Thus, the loss of E2-2 from mature pDCs and ‘‘abor-
tive’’ pDC development in the steady state yield similar CD8+
cDC subsets, which probably represent a common ‘‘default’’
fate of E2-2-deficient pDCs.
Human pDCs were first identified as efficient precursors of
cDCs in the peripheral blood (Grouard et al., 1997), as shown
by the fact that they acquire functional and morphological cDC
properties when cultured in vitro with TLR ligands and/or cyto-
kines (Soumelis and Liu, 2006). On the other hand, virus-induced
conversion of pDCs to CD8 cDCs was observed only in the BM
but not in the spleen, suggesting that mature pDCs in vivo have
lost this capacity (Zuniga et al., 2004). Notably, however, in vitro
activated pDCs reduce E2-2 expression by 75% after 2 days,
consistent with the loss of pDC lineage identity (Cisse et al.,
2008); furthermore, many E2-2 target genes such as Matn2
and Fcrla are prominently downregulated in activated pDCs
(microarray data in Iparraguirre et al., 2008). Our observations
suggest that E2-2 downregulation may play an active role after
virus-induced pDC activation, e.g., by allowing pDC conversion912 Immunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc.into cDC-like cells and/or limiting IFN secretion. This hypothesis
will be tested once a robust in vivo model of activation-induced
pDC differentiation becomes available.
E2-2 is likely to maintain the cell fate of pDCs and oppose
that of cDCs through several mechanisms. First, E2-2 binds
to a large fraction of pDC-enriched genes by ChIP, including
the key transcription factors and functional components of
TLR signaling pathway and of inhibitory receptor signaling.
These genes appear to be directly activated by E2-2, thereby
contributing to pDC gene expression program and functionality.
Second, direct targets of E2-2 may include pDC-specific
transcriptional repressors that negatively regulate cDC-en-
riched genes. One attractive candidate is Bcl11a, a transcription
factor that is highly expressed in murine and human pDCs and
B cells (Marafioti et al., 2008; Pelayo et al., 2005). Moreover,
Bcl11a is required for the development of B cells (Liu et al.,
2003) as well as of pDCs (P. Tucker, personal communication).
We found that human BCL11A promoter is a prominent E2-2
binding target and that murine Bcl11a expression is reduced
after E2-2 deletion in pDCs. This is consistent with the recent
identification of Bcl11a as a major direct target of E protein
E2a in B lymphocytes (Lin et al., 2010). Because Bcl11a is
a bona fide transcriptional repressor, it may at least partially
mediate the repression of cDC-associated gene expression
by E2-2.
Table 2. Select Targets of E2-2 Binding in Human pDCs
Gene No. Probes Rank P(Xbar) E2-2 P(Xbar) Ctrl Notes
Pathogen Sensing
ZBP1 (DAI) 2 10 0.002 0.9
PYCARD (ASC) 3 152 0.003 0.6
TLR9 8 172 0.003 0.7 IFN induction
TLR7-TLR8a 3 248 0.003 0.7 IFN induction
UNC93B1 8 16 0.002 0.1 IFN induction
Surface Receptors
LILRA4 (ILT7) 3 418 0.004 0.7 IFN inhibition; pDC specific
FCRLA 3 1271 0.006 1.0
Signal Transduction
BTK 4 531 0.004 0.8 IFN induction
TYROBP (DAP12) 2 77 0.003 0.8 IFN inhibition
PIK3AP1 (BCAP) 2 128 0.003 0.9 IFN inhibition
BLNK 3 1766 0.008 0.9 IFN inhibition
Transcription Factors
BCL11A 3 205 0.003 0.4 pDC, B cells
CIITA PIII 5 209 0.003 1.0 pDC, B cells
SPIB 5 1065 0.006 0.3 pDC, B cells
IRF7 2 453 0.004 0.3 IFN induction; pDC specific
Other PDC-Enriched
PACSIN1 3 147 0.003 0.9 pDC specific
SLA2 1 2326 0.009 0.4 pDC enriched
CD2AP 4 686 0.005 0.3 pDC enriched
PTCRA 5 1295 0.006 0.5 pDC (human), immature lymphocytes
DNTT 4 178 0.003 0.7 pDC (mouse), immature lymphocytes
BST2 4 307 0.004 0.4 pDC specific (mouse)
ChIP-on-Chip with anti-E2-2 or control antibodies was performed in human pDC cell line CAL-1. Shown are select genes among the high-confidence
list of E2-2 binding targets (Table S2), with the number of bound probes, rank of the highest signal probe, and binding probability P(Xbar) for E2-2 and
control hybridizations. The TLR-mediated IFN induction pathway and pDC-specific IFN inhibitory pathway are reviewed in Gilliet et al. (2008). Expres-
sion profiles are derived from the published data (Robbins et al., 2008).
a Binding peak located in the genomic region between TLR7 and TLR8.
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genes, as suggested by E2-2 binding to several such genes in
a pDC cell line. This may be particularly relevant for the genes
that are expressed in pDCs but at lower levels relative to cDCs,
suchas Itgax (encodingCD11c) andMHCclass II pathwaygenes.
Although E proteins primarily activate transcription, they are also
capable of repression in some cases (Kee, 2009). Notably, one
apparent target of E2-2-mediated repression is Id2, an antago-
nist of E proteins. Id2 is abundantly expressed in cDCs and is
required for the development of certain cDC subsets such as
Langerhans cells and CD8+ cDCs (Hacker et al., 2003);
conversely, its overexpression blocks pDC development in vitro
(Spits et al., 2000). Thus, the reduction of E2-2 may initiate
a feed-forward loop that further inhibits E2-2 through Id2 induc-
tion and amplifies the loss of pDC cell fate. These data suggest
a dynamic control of pDC and cDC cell fate through the bidirec-
tional inhibition between E2-2 and Id2.
Recent evidence suggests that ‘‘terminal’’ differentiation state
of a cell is in fact reversible, as first demonstrated by direct
genetic reprogramming of mature B lymphocytes into macro-Iphages (Xie et al., 2004). Furthermore, differentiated state is
often maintained by continuous expression of a single transcrip-
tional ‘‘master regulator,’’ and its removal may cause transdiffer-
entiation into a reciprocal cell fate. For instance, deletion of Pax5
from mature B cells leads to dedifferentiation into lymphoid
progenitors that give rise to T cells (Cobaleda et al., 2007). Like-
wise, the loss of FoxP3 from mature regulatory T cells abolishes
their maintenance and causes autoimmunity (Williams and
Rudensky, 2007). Our work provides another example of a post-
mitotic, long-lived, highly specialized immune cell type whose
identity is actively maintained and reversible. These results
reveal a close genetic relationship between pDCs and cDCs
and establish amodel to elucidate their unique genetic programs
and functions.EXPERIMENTAL PROCEDURES
Animals
The PTCRA-EGFP (129/SvEvTac, 129) (Shigematsu et al., 2004), Tcf4+/ (129)
(Zhuang et al., 1996), Tcf4flox (C57BL/6, B6) (Bergqvist et al., 2000), Itgax-Cremmunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc. 913
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E2-2 Maintains the Cell Fate of pDCs(B6) (Caton et al., 2007), Gt(ROSA)26Sor-CreER (B6) (Cisse et al., 2008), and
Gt(ROSA)26Sor-EYFP (mixed B6/129) (Srinivas et al., 2001) mouse strains
were used or intercrossed as indicated. For BrdU incorporation, mice were
injected with 1mg BrdU i.p. and thenmaintained for 2 weeks on drinking water
with 0.8 mg/mL BrdU (Sigma-Aldrich). For the induction of Cre recombination
in Gt(ROSA)26Sor-CreER+ mice, tamoxifen (Sigma) was administered orally
for 3 consecutive days (1 mg in 0.1 ml sunflower oil per day). Because
CreER induction per se does not affect pDC numbers or phenotype (Cisse
et al., 2008), Cre-negative Tcf4flox/flox littermates were used as controls for
Tcf4flox/floxGt(ROSA)26Sor-CreER+animals. All animal studieswereperformed
according to the investigator’s protocol approved by the Institutional Animal
Care and Use Committee of Columbia University.
Cell Analysis
Single-cell suspensions were stained for multicolor analysis with the indicated
fluorochrome-conjugated antibodies (BD PharMingen or eBioscience). For
analysis of Gt(ROSA)26Sor-CreER+ animals, DCs and pDCs were enriched
by negative selection against CD3+ and CD19+ lymphocytes via MACS
columns (Miltenyi Biotech). The samples were acquired with the LSR II flow
cytometer or sorted on FACSAria flow sorter (BD Biosciences) and analyzed
with FlowJo software (TreeStar). For BrdU incorporation, cells from 3–4 pooled
spleens were enriched for DCs and pDCs by negative selection, stained for
surface markers, fixed, permeabilized, and stained with an antibody against
BrdU according to the BD PharMingen BrdU Flow Kit protocol.
For cell morphology analysis, splenic pDCs (CD11clo EGFP+) and cDCs
(CD11chi EGFP) from PTCRA-EGFP+ Gt(ROSA)26Sor-CreER+ Tcf4flox/flox
mice and Cre-negative littermate controls 7 days after Tmx treatment were
sorted onto positively charged glass slides. Cells were fixed with 3% parafor-
maldehyde for 15 min at 37C, washed in PBS, and incubated with 100 mM
glycine for 10min at room temperature. Fixed cells were lysedwith 0.1%Triton
X-100 for 4 min, washed with PBS, blocked with 1% BSA, and stained with
Rhodamine-phalloidin (Cytoskeleton, Inc.) and DAPI. Images were acquired
with LSM 710 NLO confocal microscope and ConfoCor 3 imager (Carl Zeiss).
For semiquantitative analysis of cell morphology, images of individual pDCs in
the same central plane were coded and scored by a blinded observer for three
categories: irregular shape, actin rearrangement to cell periphery, and
dendrites. Each category was scored from0 (none) to 3 (maximal), and a cumu-
lative score was derived for each cell.
T Cell Proliferation
Splenic CD11c+ cells from PTCRA-EGFP+Gt(ROSA)26Sor-CreER+ Tcf4flox/flox
mice and Cre-negative littermate controls 7 days after Tmx treatment were en-
riched by positive selection via MACS columns (Miltenyi Biotech), and pDCs
(CD11clo EGFP+) and cDCs (CD11chi EGFP) were sorted. Allogeneic CD4+
T cells (>95% purity) were isolated from spleens of Balb/c mice via negative
selection of CD11c, B220, Ter119, CD8, DX5, and CD11b-expressing cells
on MACS columns. Cells were cultured for 72 hr at 1:20 DC to T cell ratio,
and [3H]-thymidine incorporation for the last 18 hr of culture was determined
via b-counter.
Gene Expression Analysis
For microarray analysis, Gt(ROSA)26Sor-CreER+ Tcf4flox/flox mice and Cre-
negative littermate controls were treated with Tmx, and 4 or 6 days later sple-
nocytes were isolated, pooled, and enriched for lineage (CD3, CD19)-negative
cells via MACS columns. The pDCs (CD11b B220+ CD11clo Bst2+) were
sorted directly into Trizol reagent (Invitrogen), and total RNA was reverse tran-
scribed, amplified, labeled, and hybridized in duplicates to Mouse Genome
430 2.0 arrays (Affymetrix) as described (Cisse et al., 2008). Principal compo-
nent analysis was done with the NIA Array software (Sharov et al., 2005).
Normal gene expression profiles were derived from GEO data set GSE9810
(Robbins et al., 2008).
For qRT-PCR analysis, RNA from pDCs or cDCs (CD11chi Bst2) isolated as
above on day 5 after Tmx treatment was reverse transcribed and assayed by
SYBR Green-based real-time PCR with MX3000P instrument (Stratagene).
The expression of all genes was normalized to that of b-actin and expressed
relative to the indicated reference sample via the DDCT method. All primers
were validated for linear amplification (sequences available upon request).914 Immunity 33, 905–916, December 22, 2010 ª2010 Elsevier Inc.Chromatin Immunoprecipitation
Cells of the human pDC lymphoma line CAL-1 (Maeda et al., 2005) were cross-
linked with formaldehyde, sonicated, and subjected to immunoprecipitation
with anti-E2-2mAb (Bain et al., 1993) ormouse IgG control as described (Cisse
et al., 2008). After crosslink reversal, the isolated chromatin was amplified,
labeled, and hybridized to Human Promoter ChIP-on-chip Microarray Set
(Agilent Technologies) according to manufacturer’s instructions. Hybridized
microarrays were scanned and analyzed with DNA Analytics software (Agilent
Technologies).
Statistical Analysis
Statistical significance was estimated via unpaired, two-tailed Student’s t test.
ACCESSION NUMBERS
The microarray data for gene expression and chromatin immunoprecipitation
analysis are available in the Gene Expression Omnibus (GEO) database (http://
www.ncbi.nlm.nih.gov/gds) under the accession number GSE24785.
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